On April 9, 2019, the Department of Justice announced that Indivior Inc. (INVVY) was indicted for fraudulently marketing prescription opioids. According to the Department of Justice, Indivior, Inc. lied to doctors and public health care benefit programs about the safety of Suboxone Film. Almost immediately after the indictment was announced, INVVY stock crashed and lost over 70% of its value.
Our law firm is investigating a shareholder claim by holders of INVVY. If you or someone you know purchased INVVY and sustained losses because of the criminal indictment, we want to speak with you. We have assembled links to the following relevant investigatory documents for shareholders:
The indictment against Indivior concerns its deceptive marketing of Suboxone Film. Indivior developed Suboxone in 2007 as an alternative to the tablet form of Suboxone. The primary ingredient in both Suboxone Film and Suboxone Tablets is buprenorphine, a highly potent opioid. Indivior aggressively marketed Suboxone Film as safer than the tablet form, even though, according to the indictment, Indivior lacked any scientific evidence to support those claims. According to the indictment against Indivior, Indivior obtained billions of dollars in revenue from Suboxone Film prescriptions by deceiving health care providers into believing that Suboxone Film was safer, less divertible and less abusable than other opioid-addiction treatments.
The indictment charges Indivior with conspiracy to commit wire fraud, mail fraud and health care fraud. An indictment alleges that crimes have been committed and all defendants are presumed innocent by law until proven guilty. In response to the indictment, Indivior, Inc. released a press release denying the allegations calling them, “fundamentally wrong.” INVVY also states that it will “vigorously” contest the charges.
We are investigating shareholder claims related to Indivior’s indictment and invite shareholders to contact our office for a free consultation by calling 212-658-1500 or emailing firstname.lastname@example.org. Don’t delay.